The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy.
The drug is called tirzepatide and will be sold under the name Zepbound.
Patients who used tirzepatide lost an average of 18 percent of their body weight, according to the F.D.A., when it was taken at its highest dose in a drug trial.
That’s compared with Wegovy, manufactured by Novo Nordisk, which produced an average 15 percent weight loss.
approved Zepbound for people with obesity and for those who are overweight and have at least one obesity-related condition.
Persons:
Eli Lilly, tirzepatide
Organizations:
Drug Administration, Novo Nordisk